Journal
BIOMATERIALS
Volume 32, Issue 35, Pages 9328-9342Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2011.08.066
Keywords
Oncolytic adenovirus; Arginine-grafted bioreducible polymer; Chemical conjugation; Cationic polymer; Systemic delivery of Ad
Funding
- Ministry of Knowledge Economy [10030051]
- National Research Foundation of Korea [R15-2004-024-02001-0, 2010-0029220, 2009K001644]
- Korea Food and Drug Administration [KFDA-11172-358]
- Ministry of Education, Science and Technology, Korea [WCU 200900000000024]
- National Institutes of Health, USA [CA 107070]
- National Research Foundation of Korea [R15-2004-024-02001-0] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Systemic administration of adenovirus (Ad) vectors is complicated by host immune responses and viral accumulation in the liver, resulting in a short circulatory virus half-life, low efficacy, and host side effects. Ad surface modification is thus required to enhance safety and therapeutic efficacy. An arginine-grafted bioreducible polymer (ABP) was chemically conjugated to the Ad surface, generating Ad-Delta E1/GFP-ABP. A hepatocellular carcinoma [HCC]-selective oncolytic Ad complex, YKL-1001-ABP, was also generated. Transduction efficiency of Ad-Delta E1/GFP-ABP was enhanced compared to naked Ad-Delta E1/GFP. YKL-1001-ABP elicited an enhanced and specific killing effect in liver cancer cells (Huh7 and HepG2) expressing alpha-fetoprotein (AFP). Compared with naked Ad, systemic administration of ABP-conjugated Ad resulted in reduced liver toxicity and interleukin (IL)-6 production in vitro and in vivo. Ad-Delta E1/GFP-ABP was more resistant to the neutralizing effects of human serum compared to naked Ad-Delta E1/GFP. ABP conjugation extended blood circulation time 45-fold and reduced anti-Ad Ab neutralization. Moreover, systemic administration of YKL-1001-ABP markedly suppressed growth of Huh7 hepatocellular carcinoma. These results demonstrate that chemical conjugation of ABP to the Ad surface improves safety and efficacy, indicating that ABP-conjugated Ad is a potentially useful cancer therapeutic agent to target cancer via systemic administration. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available